Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ: BIOA )

23.86 +0.87 (+3.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioAge Labs, Inc. - Common Stock

Prediction: These 2 Stocks Could Soar in 2025
The key word here is "could." 
Via The Motley Fool
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs. 
Via The Motley Fool
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
One of these businesses is a risky play, but the other is very likely to succeed. 
Via The Motley Fool
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October
There's a chance that its lead candidate could become one of the top drugs ever. 
Via The Motley Fool
This IPO Biotech Stock Could Be the Next Eli Lilly
BioAge has its eyes on a handful of truly gargantuan markets. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
From BioAge Labs, Inc.
Via GlobeNewswire
Obesity Drug Developer BioAge Makes Nasdaq Debut
Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials. 
Via Talk Markets
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
The company is working on a drug that mimics apelin, which is released following exercise. 
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.